medica glp 1 coverage As more Americans turn to GLP-1 drugs for weight loss, Medicare is launching a limited program to expand access for eligible beneficiaries Have you heard? There's a

BMO Capitals Evan Seigerman and other analysts say that this advantage may not last long, but being the first to market gives you important revenue visibility through at least 2026

Subcutaneous Injection Mechanism: Direct injection into the subcutaneous fat layer, bypassing barriers like the digestive or nasal mucosa

Special Population Considerations Certain populations may need modified protocols

This analysis examines CMSs Medicare Part D claims data from 2019 to 2024 to document the increase in the number of beneficiaries being treated with GLP-1 drugs and the growth in Medicare spending and claims for GLP-1s

ProHealth's cited clinical study (Dosz E et al., Nutraceuticals, 2025) reported a 26.4% improvement in digestive comfort associated with ButyroGen at the ingredient level